Key Highlights
• Leadership team in place: Following appointment as Nigel Lange as CEO, key recent hires include a Chief Medical Officer, Head of Medical Affairs, Director of Access Reimbursement, Economics and Assessment and Director of Clinical development
• Finalising data package for HDE submission: Currently finalising an updated dataset which involves a more recent data cut-off point, to support its HDE application to the FDA
• Targeting hospitals in Greater London in the near-term: Pushing forward with launch preparation activities throughout Europe including establishing the Osprey registry
• Additional sales in New Zealand: Following OncoSil’s first ever commercial sale, OncoSil has achieved further sales in New Zealand
• Cash position: Cash balance of $15.3 million as at 31 March 2021
Ann: Appendix 4C - quarterly, page-4
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.001(7.69%) |
Mkt cap ! $23.78M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.6¢ | $34.37K | 5.002M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 4929003 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 23400459 | 26 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| OSL (ASX) Chart |